Novartis pays $422.5 Million in Whistleblower case over improper marketing

Swiss drug manufacturer Novartis will pay $422.5 million to settle civil and criminal charges for improper marketing of an antiseizure medicine Trileptal and five other drugs. The company was accused of paying kickbacks to healthcare professionals through speaker programs, advisory boards, entertainment, travel and meals. Novartis stock fell 1 percent an hour before the 1 p.m. announcement. The 5 other drugs are Diovan, Sandostatin, Exforge, tekturna. and Zelnorm.